Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
International Journal of Genomics
Volume 2014, Article ID 312102, 7 pages
http://dx.doi.org/10.1155/2014/312102
Research Article

A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer

Department of Stomatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, No. 1 Yixueyuan Road, Chongqing 400016, China

Received 7 June 2014; Accepted 9 September 2014; Published 21 October 2014

Academic Editor: Henry Heng

Copyright © 2014 Yinsheng Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. I. Nicholson, J. M. W. Gee, and M. E. Harper, “EGFR and cancer prognosis,” European Journal of Cancer, vol. 37, supplement 4, pp. S9–S15, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. M. W. Saif, “Colorectal cancer in review: the role of the EGFR pathway,” Expert Opinion on Investigational Drugs, vol. 19, no. 3, pp. 357–369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. P. M. Forde and D. S. Ettinger, “Targeted therapy for non-small-cell lung cancer: past, present and future,” Expert Review of Anticancer Therapy, vol. 13, no. 6, pp. 745–758, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Montemurro and M. Scaltriti, “Biomarkers of drugs targeting HER-family signalling in cancer,” Journal of Pathology, vol. 232, no. 2, pp. 219–229, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. A. W. Burgess, H.-S. Cho, C. Eigenbrot et al., “An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors,” Molecular Cell, vol. 12, no. 3, pp. 541–552, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. W. A. Cooper, D. C. Lam, S. A. O'Toole, and J. D. Minna, “Molecular biology of lung cancer,” Journal of Thoracic Disease, vol. 5, pp. S479–S490, 2013. View at Google Scholar
  7. C. R. Chong and P. A. Jänne, “The quest to overcome resistance to EGFR-targeted therapies in cancer,” Nature Medicine, vol. 19, no. 11, pp. 1389–1400, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. G. G. Gomez, J. Wykosky, C. Zanca, F. B. Furnari, and W. K. Cavenee, “Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks,” Cancer Biology and Medicine, vol. 10, no. 4, pp. 192–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Moriai, M. S. Kobrin, C. Hope, L. Speck, and M. Korc, “A variant epidermal growth factor receptor exhibits altered type α transforming growth factor binding and transmembrane signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 21, pp. 10217–10221, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Moriai, M. S. Kobrin, and M. Korc, “Cloning of a variant epidermal growth factor receptor,” Biochemical and Biophysical Research Communications, vol. 191, no. 3, pp. 1034–1039, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. E. M. Poole, K. Curtin, L. Hsu et al., “Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer,” International Journal of Molecular Epidemiology and Genetics, vol. 2, no. 4, pp. 300–315, 2011. View at Google Scholar · View at Scopus
  12. I. Kallel, M. Rebai, A. Khabir, N. R. Farid, and A. Rebaï, “Genetic polymorphisms in the egfr (R521K) and estrogen receptor (T594T) genes, EGFR and erbb-2 protein expression, and breast cancer risk in tunisia,” Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 753683, 6 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Wu, W. Zhang, A. Xu et al., “Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis b virus-related hepatocellular carcinoma in the population of north China,” Genetic Testing and Molecular Biomarkers, vol. 17, no. 8, pp. 595–600, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Zhang, Z. Zhan, J. Wu et al., “Association among polymorphisms in EGFR gene exons, lifestyle and risk of gastric cancer with gender differences in Chinese Han subjects,” PLoS ONE, vol. 8, no. 3, Article ID e59254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. E. Choi, S. H. Park, K. M. Kim et al., “Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study,” BMC Cancer, vol. 7, article 199, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. H. Torres-Jasso, A. R. Bustos-Carpinteyro, M. E. Marín et al., “Analysis of the polymorphisms EGFR-R521K and ERBB2-I655V in Mexican patients with gastric cancer and premalignant gastric lesions,” Revista de Investigación Clínica, vol. 65, no. 2, pp. 150–155, 2013. View at Google Scholar · View at Scopus
  17. J.-X. Xie, J.-H. Yin, Q. Zhang et al., “Association of genetic polymorphisms of key molecules in JAK/STAT signaling pathway with susceptibility of hepatocellular carcinoma,” Zhonghua Liu Xing Bing Xue Za Zhi, vol. 33, no. 2, pp. 215–219, 2012. View at Google Scholar · View at Scopus
  18. M. Martinelli, G. Ugolini, L. Scapoli et al., “The EGFR R521K polymorphism influences the risk to develop colorectal cancer,” Cancer Biomarkers, vol. 8, no. 2, pp. 61–65, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Rebaï, I. Kallel, F. Hamza et al., “Association of EGFR and HER2 polymorphisms with risk and clinical features of thyroid cancer,” Genetic Testing and Molecular Biomarkers, vol. 13, no. 6, pp. 779–784, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. N. R. Abdraboh, H. H. Shehata, M. B. Ahmed, and F. A. Bayoumi, “HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer,” Disease Markers, vol. 34, no. 6, pp. 407–417, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. O. H. Mustafa, A. R. Hamzeh, L. Ghabreau, N. Akil, A.-E. Almoustafa, and A. Alachkar, “Allele frequencies of the epidermal growth factor receptors polymorphism R521K in colorectal cancer patients and healthy subjects indicate a risk-reducing effect of K521 in Syrian population,” North American Journal of Medical Sciences, vol. 5, no. 3, pp. 202–206, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. C. Sobti, M. Askari, M. Nikbakht, N. Singh, S. C. Sharma, and A. M. Abitew, “Genetic variants of EGFR (142285>A) and ESR1 (2014>A) gene polymorphisms and risk of breast cancer,” Molecular and Cellular Biochemistry, vol. 369, no. 1-2, pp. 217–225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. Y.-S. Hong, S. L. Deming, Y.-T. Gao et al., “A two-stage case-control study of EGFR polymorphisms and breast cancer risk,” Cancer Epidemiology Biomarkers & Prevention, vol. 18, no. 2, pp. 680–683, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Publisher · View at Google Scholar · View at Scopus
  25. C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. K. M. Ferguson, “Structure-based view of epidermal growth factor receptor regulation,” Annual Review of Biophysics, vol. 37, pp. 353–373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Arkhipov, Y. Shan, R. Das et al., “Architecture and membrane interactions of the EGF receptor,” Cell, vol. 152, no. 3, pp. 557–569, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Liu, T. E. Cleveland IV, S. Bouyain, P. O. Byrne, P. A. Longo, and D. J. Leahy, “A single ligand is sufficient to activate EGFR dimers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 27, pp. 10861–10866, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Mattoon, P. Klein, M. A. Lemmon, I. Lax, and J. Schlessinger, “The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 4, pp. 923–928, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. Q. Zheng, R. Chen, L. Luan, J. Li, and S. Gao, “The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer,” Tumor Biology, vol. 35, no. 3, pp. 2383–2389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. W.-S. Wang, P.-M. Chen, T.-J. Chiou et al., “Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma,” Clinical Cancer Research, vol. 13, no. 12, pp. 3597–3604, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Bandrés, R. Barricarte, C. Cantero et al., “Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients,” Oral Oncology, vol. 43, no. 7, pp. 713–719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Sasaki, K. Okuda, S. Shimizu et al., “EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 2, pp. 313–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. Y.-Y. Hsieh, C.-H. Tzeng, M.-H. Chen, P.-M. Chen, and W.-S. Wang, “Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy,” Cancer Science, vol. 103, no. 4, pp. 791–796, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. S. Leite, L. C. Giacomin, D. N. Piranda et al., “Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer,” BMC Cancer, vol. 14, article 190, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Ma, T. Sun, Y. Shi et al., “Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib,” Lung Cancer, vol. 66, no. 1, pp. 114–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Dahan, E. Norguet, M.-C. Etienne-Grimaldi et al., “Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer,” BMC Cancer, vol. 11, article 496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Lurje, F. Nagashima, W. Zhang et al., “Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab,” Clinical Cancer Research, vol. 14, no. 23, pp. 7884–7895, 2008. View at Publisher · View at Google Scholar
  40. C.-Y. Lai, F.-C. Sung, L.-L. Hsieh et al., “Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy,” Annals of Surgical Oncology, vol. 20, no. 3, pp. S599–S606, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. W. Zhang, D. J. Park, B. Lu et al., “Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation,” Clinical Cancer Research, vol. 11, no. 2I, pp. 600–605, 2005. View at Google Scholar · View at Scopus
  42. G. Liu, S. Gurubhagavatula, W. Zhou et al., “Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib,” Pharmacogenomics Journal, vol. 8, no. 2, pp. 129–138, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Shitara, H. Sasaki, K. Yokota et al., “Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients,” Experimental and Therapeutic Medicine, vol. 4, no. 5, pp. 785–789, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. S. D. Horne, S. A. Pollick, and H. H. Q. Heng, “Evolutionary mechanism unifies the hallmarks of cancer,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  45. H. H. Heng, S. W. Bremer, J. B. Stevens et al., “Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution,” Cancer and Metastasis Reviews, vol. 32, no. 3-4, pp. 325–340, 2013. View at Publisher · View at Google Scholar · View at Scopus